PharmGen Science (004720) Fundamentals 2026 — Revenue Analysis | SniperIQ
PharmGen Science (004720) is a KR-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₩61.4B, trading at ₩3380.00 on the KSC. This SniperIQ fundamentals page covers PharmGen Science's valuation, profitability (net margin -67.4%), revenue (₩173.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PharmGen Science's market cap?
PharmGen Science (004720) has a market capitalization of approximately ₩61.4B, trading at ₩3380.00 on the KSC. Market cap moves with the live share price.
What is PharmGen Science's P/E ratio?
PharmGen Science's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PharmGen Science?
PharmGen Science runs a net profit margin of -67.4%, a gross margin of 64.8%, and an operating margin of 3.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PharmGen Science generate?
PharmGen Science reported revenue of ₩173.1B for fiscal year 2025, with net income of -₩116.6B and earnings per share (EPS) of -5312.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PharmGen Science pay a dividend?
PharmGen Science does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PharmGen Science financially healthy?
PharmGen Science carries a debt-to-equity ratio of 0.04x and a current ratio of 2.90x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PharmGen Science a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PharmGen Science (004720) the key facts are: market cap ₩61.4B, revenue ₩173.1B, 52-week range 2590-5490. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PharmGen Science's full fundamentals live
Get PharmGen Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.